Free tool
Rare disease stocks
We cover 12 companies grouped under the Rare disease theme. The median market value in the group is $659.46M. Across the group, the median move over the past trading day is +0.35%. Price change over the past year runs from −31.7% to +155.2% across the middle 80 percent of the group, with a median of +24.2%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
12 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return | Next report |
|---|---|---|---|---|---|---|
| ARGX | argenx SE | $1,019.49 | +14.70% | +21.37% | +50.52% | Oct 22, 2026 |
| BMRN | BioMarin Pharmaceutical Inc. | $66.12 | +9.71% | +11.22% | +13.03% | Oct 26, 2026 |
| ABVX.PA | ABIVAX Société Anonyme | 98.10 EUR | −9.83% | −14.70% | +42.59% | Sep 21, 2026 |
| 0HNC.L | BioMarin Pharmaceutical Inc. | $66.16 | +0.37% | +11.49% | +12.68% | Oct 26, 2026 |
| GNFT.PA | Genfit S.A. | 13.90 EUR | +5.30% | +164.76% | +293.99% | Sep 29, 2026 |
| RZLT | Rezolute, Inc. | $5.01 | +1.42% | +131.41% | −28.43% | Sep 16, 2026 |
| CUV.AX | Clinuvel Pharmaceuticals Limited | 10.54 AUD | +7.44% | −17.07% | −21.84% | Aug 27, 2026 |
| XUP.DE | Genfit S.A. | 14.08 EUR | −1.81% | +164.41% | +166.82% | Sep 29, 2026 |
| 0AB6.L | Hyloris Pharmaceuticals SA | 4.46 EUR | −0.66% | −37.71% | −32.01% | Sep 24, 2026 |
| INM | InMed Pharmaceuticals Inc. | $1.44 | −12.20% | +28.57% | −35.43% | Sep 23, 2026 |
| 1AE.DE | argenx SE | 879.20 EUR | +14.06% | +21.37% | +35.39% | Oct 22, 2026 |
| 2X1.DE | ABIVAX Société Anonyme | 101.90 EUR | −6.43% | −11.08% | +35.69% | Sep 21, 2026 |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.